EMBO Molecular Medicine (Jun 2024)

A multispectral 3D live organoid imaging platform to screen probes for fluorescence guided surgery

  • Bernadette Jeremiasse,
  • Ravian L van Ineveld,
  • Veerle Bok,
  • Michiel Kleinnijenhuis,
  • Sam de Blank,
  • Maria Alieva,
  • Hannah R Johnson,
  • Esmée J van Vliet,
  • Amber L Zeeman,
  • Lianne M Wellens,
  • Gerard Llibre-Palomar,
  • Mario Barrera Román,
  • Alessia Di Maggio,
  • Johanna F Dekkers,
  • Sabrina Oliveira,
  • Alexander L Vahrmeijer,
  • Jan J Molenaar,
  • Marc HWA Wijnen,
  • Alida FW van der Steeg,
  • Ellen J Wehrens,
  • Anne C Rios

DOI
https://doi.org/10.1038/s44321-024-00084-4
Journal volume & issue
Vol. 16, no. 7
pp. 1495 – 1514

Abstract

Read online

Abstract Achieving complete tumor resection is challenging and can be improved by real-time fluorescence-guided surgery with molecular-targeted probes. However, pre-clinical identification and validation of probes presents a lengthy process that is traditionally performed in animal models and further hampered by inter- and intra-tumoral heterogeneity in target expression. To screen multiple probes at patient scale, we developed a multispectral real-time 3D imaging platform that implements organoid technology to effectively model patient tumor heterogeneity and, importantly, healthy human tissue binding.

Keywords